Bio-Rad Laboratories Statistics
Want to see BIO full AI Analyst Report?
Bio-Rad Laboratories (BIO) Stock Statistics & Valuation Metrics
Total Valuation
Bio-Rad Laboratories has a market cap or net worth of $9.74B. The enterprise value is $9.87B.
- Market Cap
- $9.74B
- Enterprise Value
- $9.87B
Share Statistics
Bio-Rad Laboratories has 21,832,130 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 21,832,130
- Owned by Insiders
- 37.17%
- Owned by Institutions
- 54.86%
Financial Efficiency
Bio-Rad Laboratories’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 2.04%.
- Return on Equity (ROE)
- 0.10
- Return on Assets (ROA)
- 0.07
- Return on Invested Capital (ROIC)
- 2.04%
- Return on Capital Employed (ROCE)
- 0.03
- Revenue Per Employee
- 346.74K
- Profits Per Employee
- 102.00K
- Employee Count
- 7,450
- Asset Turnover
- 0.24
- Inventory Turnover
- 1.67
Valuation Ratios
The current PE Ratio of Bio-Rad Laboratories is 9.41. Bio-Rad Laboratories’s PEG ratio is 0.03.
- PE Ratio
- 9.41
- PS Ratio
- 3.73
- PB Ratio
- 1.27
- Price to FCF
- 29.35
- Price to Operating Cash Flow
- 20.55
- PEG Ratio
- 0.03
Income Statement
In the last 12 months, Bio-Rad Laboratories had revenue of 2.58B and earned 759.90M in profits. Earnings per share was 27.87.
- Revenue
- 2.58B
- Gross Profit
- 1.34B
- Operating Income
- 270.50M
- Pretax Income
- 995.50M
- Net Income
- 759.90M
- EBITDA
- 1.21B
- Earnings Per Share (EPS)
- 27.87
Cash Flow
In the last 12 months, operating cash flow was 468.10M and capital expenditures -139.00M, giving a free cash flow of 329.10M billion.
- Operating Cash Flow
- 468.10M
- Free Cash Flow
- 329.10M
- Free Cash Flow per Share
- 12.29
Dividends & Yields
Bio-Rad Laboratories pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 3.40%
- Earnings Yield
- 10.63%
Stock Price Statistics
- Beta
- 0.81
- 52-Week Price Change
- 17.80%
- 50-Day Moving Average
- 372.95
- 200-Day Moving Average
- 317.11
- Relative Strength Index (RSI)
- 42.22
- Average Volume (3m)
- 255.79K
Important Dates
Bio-Rad Laboratories upcoming earnings date is Feb 18, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Feb 18, 2027
- Ex-Dividend Date
- ―
Financial Position
Bio-Rad Laboratories as a current ratio of 5.62, with Debt / Equity ratio of 20.54%
- Current Ratio
- 5.62
- Quick Ratio
- 4.19
- Debt to Market Cap
- 0.17
- Net Debt to EBITDA
- 0.83
- Interest Coverage Ratio
- 5.52
Taxes
In the past 12 months, Bio-Rad Laboratories has paid 235.60M in taxes.
- Income Tax
- 235.60M
- Effective Tax Rate
- 0.24
Enterprise Valuation
Bio-Rad Laboratories EV to EBITDA ratio is 7.13, with an EV/FCF ratio of 32.10.
- EV to Sales
- 4.07
- EV to EBITDA
- 7.13
- EV to Free Cash Flow
- 32.10
- EV to Operating Cash Flow
- 22.57
Balance Sheet
Bio-Rad Laboratories has $1.66B in cash and marketable securities with $1.36B in debt, giving a net cash position of $300.90M billion.
- Cash & Marketable Securities
- $1.66B
- Total Debt
- $1.36B
- Net Cash
- $300.90M
- Net Cash Per Share
- $13.78
- Tangible Book Value Per Share
- $258.61
Margins
Gross margin is 51.26%, with operating margin of 4.59%, and net profit margin of 39.45%.
- Gross Margin
- 51.26%
- Operating Margin
- 4.59%
- Pretax Margin
- 50.92%
- Net Profit Margin
- 39.45%
- EBITDA Margin
- 57.14%
- EBIT Margin
- 52.34%
Analyst Forecast
The average price target for Bio-Rad Laboratories is $440.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $440.00
- Price Target Upside
- 22.84% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- 1.38%
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 1
- AI Score
- 71

